Coherus Oncology reported that the Phase 3 JUPITER‑02 trial of its PD‑1 inhibitor LOQTORZI® (toripalimab‑tpzi) in combination with chemotherapy has produced a six‑year overall survival (OS) follow‑up. The median OS for patients receiving LOQTORZI plus chemotherapy was 64.8 months, compared with 33.7 months for chemotherapy alone, a 31‑month improvement and a 38 % reduction in the risk of death (hazard ratio 0.62, 95 % CI 0.45–0.85).
The data reinforce LOQTORZI’s position as the preferred first‑line therapy for recurrent or metastatic nasopharyngeal carcinoma (RM‑NPC) and support the company’s strategy to expand the drug’s label through combination regimens. The durable survival advantage, nearly doubling median OS, is a key driver of investor enthusiasm and is expected to strengthen payer and clinician discussions.
In Q3 2025, Coherus reported a non‑GAAP net loss of $38.9 million, or $(0.33) per share, slightly beating consensus estimates of $(0.34). Revenue for the quarter was $11.6 million, driven by a 12 % increase from Q2 2025 and a 92 % jump from Q3 2024, reflecting robust demand for LOQTORZI in the core RM‑NPC market. The earnings beat was largely attributable to disciplined cost management that offset the higher revenue mix.
CEO Denny Lanfear said the six‑year data confirm the company’s strategy to deliver life‑extending therapies. “The long‑term survival benefit demonstrates the clinical value of LOQTORZI and validates our focus on expanding its use in combination settings,” he said. Chief Medical Officer Rosh Dias added, “These results reinforce LOQTORZI plus chemotherapy as the standard of care for patients with RM‑NPC.” External expert Victoria Villaflor noted that the data give clinicians greater confidence in using toripalimab for this aggressive cancer.
Coherus is leveraging the JUPITER‑02 success to accelerate development of additional immuno‑oncology candidates, including CHS‑114, a CCR8 Treg depleter, and casdozokitug, an IL‑27 antagonist. The company’s cash position of $191.7 million as of September 30, 2025, provides a runway to pursue these programs while maintaining a focus on commercial growth for LOQTORZI.
The six‑year survival benefit positions LOQTORZI as a cornerstone of Coherus’s oncology portfolio and strengthens the company’s competitive advantage in a market where durable outcomes are scarce. The data are expected to support future label expansions, enhance payer negotiations, and drive continued revenue growth in the nasopharyngeal carcinoma indication.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.